6:57 PM
 | 
Mar 20, 2015
 |  BC Extra  |  Clinical News

Prothena soars on Phase I Parkinson's data

Prothena Corp. plc (NASDAQ:PRTA) rose $9.43 (32%) to $38.66 on Friday after it said Parkinson's disease (PD) candidate PRX002 reduced free serum alpha synuclein ( SNCA) levels...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >